Adhesion G Protein-Coupled Receptor G2 Promotes Hepatocellular Carcinoma Progression and Serves as a Neutrophil-Related Prognostic Biomarker
International Journal of Molecular Sciences · 2023
DOI: 10.3390/ijms242316986 ↗Kurz gefasst
Fachartikel in der Zeitschrift International Journal of Molecular Sciences, 2023. Verfasst von Qian Wu und 8 weiteren Autor:innen. Beteiligte Einrichtung: College of Life Science, Yangtze University, Jingzhou 434025, China. Hauptthemen laut MEDLINE: Carcinoma, Hepatocellular, Liver Neoplasms, MicroRNAs. Die Arbeit wurde bisher 7-mal zitiert (Crossref) und nennt 64 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: National Natural Science Foundation of China, Natural Science Foundation of Hubei Province, Scientific research plan project of Hubei Provincial Department of Education.
Abstract (Originalsprache)
Adhesion G protein-coupled receptor G2 (ADGRG2) is an orphan adhesion G protein-coupled receptor (GPCR), which performs a tumor-promoting role in certain cancers; however, it has not been systematically investigated in hepatocellular carcinoma (HCC). In the current study, we utilized multiple databases to analyze the expression and diagnostic and prognostic value of ADGRG2 in HCC and its correlation with immune infiltration and inflammatory factors. The function and upstream regulatory miRNA of ADGRG2 were validated through qPCR, Western blot, CCK8, wound healing, and dual luciferase assays. It turned out that ADGRG2 was significantly higher in HCC and had a poor survival rate, especially in AFP ≤ 400 ng/mL subgroups. Functional enrichment analysis suggested that ADGRG2 may be involved in cancer pathways and immune-related pathways. In vitro, siRNA-mediated ADGRG2 silencing could inhibit the proliferation and migration of Huh7 and HepG2 cells. There was a highly significant positive correlation between ADGRG2 and neutrophils. Moreover, NET-related genes were filtered and confirmed, such as ENO1 and S100A9. Meanwhile, the high expression of ADGRG2 was also accompanied by the highest number of inflammatory cytokines, chemokines, and chemokine receptors and good immunotherapy efficacy. Finally, AGDGR2 may be sensitive to two drugs (PIK-93 and NPK76-II-72-1) and can be targeted by miR-326. In conclusion, ADGRG2 may serve as a novel biomarker and drug target for HCC diagnosis, immunotherapy, and prognosis and was related to neutrophils and the inflammatory process of liver cancer development.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- College of Life Science, Yangtze University, Jingzhou 434025, China.
- State Key Laboratory of Freshwater Ecology and Biotechnology, Institute of Hydrobiology, Chinese Academy of Sciences, Wuhan 430072, China.
Förderung
- National Natural Science Foundation of China
- Natural Science Foundation of Hubei Province
- Scientific research plan project of Hubei Provincial Department of Education
- Innovation and Entrepreneurship Training Program for College Students of Yangtze University
Zitieren
APA
Wu, Q., Wang, P., Peng, Q., Kang, Z., Deng, Y., Li, J., Chen, Y., Li, J., & Ge, F. (2023). Adhesion G Protein-Coupled Receptor G2 Promotes Hepatocellular Carcinoma Progression and Serves as a Neutrophil-Related Prognostic Biomarker. International Journal of Molecular Sciences. https://doi.org/10.3390/ijms242316986
Vancouver
Wu Q, Wang P, Peng Q, Kang Z, Deng Y, Li J, et al. Adhesion G Protein-Coupled Receptor G2 Promotes Hepatocellular Carcinoma Progression and Serves as a Neutrophil-Related Prognostic Biomarker. International Journal of Molecular Sciences. 2023. doi:10.3390/ijms242316986
BibTeX
@article{Wu2023,
author = {Wu, Qian and Wang, Pei and Peng, Qihang and Kang, Zhongcui and Deng, Yiting and Li, Jiayi and Chen, Ying and Li, Jin and Ge, Feng},
title = {Adhesion G Protein-Coupled Receptor G2 Promotes Hepatocellular Carcinoma Progression and Serves as a Neutrophil-Related Prognostic Biomarker},
journal = {International Journal of Molecular Sciences},
year = {2023},
doi = {10.3390/ijms242316986}
}
EUVIMED